Brands push up Hypera's sales
This article was originally published in OTC Bulletin & The Rose Sheet
Executive Summary
Brazil’s Hypera Pharma – formerly known as Hypermarcas – said a rise in group sales of 12.7% to BRL3.64 billion (€898 million) in 2017 had been “mostly derived from the performance of branded products” in the firm’s Branded Prescription and Consumer Health business units.